<DOC>
	<DOCNO>NCT00440804</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness ibuprofen l-lysine iv premature infant early treatment Patent Ductus Arteriosus .</brief_summary>
	<brief_title>Safety Efficacy Study Ibuprofen l-Lysine Solution Premature Infants Treatment PDA</brief_title>
	<detailed_description>The ductus arteriosus remain patent 40 % 80 % low birth weight infant . Early treatment intravenous ibuprofen L-lysine ( IV ibuprofen ) suggest preliminary study close ductus shorten hospital stay . This study aim determine effect early treatment IV ibuprofen give low birth weight infant non-symptomatic patent ductus arteriosus ( PDA ) less 72 hour life accelerate maintain ductal closure , thereby reduce need rescue therapy .</detailed_description>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Premature newborn infant either gender birth weight 500 1000 gram , appropriate gestational age ; Nonsymptomatic PDA evidence ductal shunt document echocardiogram ( ECHO ) ; Less 72 hour age time randomization ; If infant one multiple birth , he/she one two ( 2 ) old infant meet eligibility criterion ; Consent form sign parent . Either major congenital malformation and/or chromosomal anomaly ; Proven , severe congenital bacterial infection ; Maternal antenatal nonsteroidal antiinflammatory drug ( NSAID ) exposure &lt; 72 hour prior delivery ; Treatment pharmacological replacement steroid therapy anytime since birth ; Unremitting shock require high dos vasopressor ( i.e . inability maintain mean arterial blood pressure appropriate gestational age Â± 2 SD use volume maximal vasopressor therapy define individual institution ) ; Renal failure oliguria define urine flow rate &lt; 0.5 mL/kg/hr 8 hour prior randomization ( Anuria acceptable infant first 24 hour life ) ; Platelet count &lt; 75,000/mm 3 ; Clinical bleeding tendency ( i.e . ooze puncture site ) ; Expected survival le 48 hour opinion attend neonatologist ; Participation clinical intervention trial . Exceptions may make approve Medical Director designee , RPD Pharmaceutical Department ; Symptomatic PDA document 3 follow 5 criterion Bounding pulse Hyperdynamic precordium Pulmonary edema Increased cardiac silhouette Systolic murmur Or , view neonatologist deem hemodynamically significant ductus . Exposure NSAIDs time since birth .</criteria>
	<gender>All</gender>
	<minimum_age>28 Weeks</minimum_age>
	<maximum_age>34 Weeks</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>patent ductus arterious</keyword>
</DOC>